Clinical trial Recruiting at 5 sites Observational Ages 18 and up

Using heart rate variability to predict brain injury after cardiac arrest

Official title: Heart Rate Variability in Early Prediction of a Noxic Brain Injury After Cardiac Arrest

Run by CMC Ambroise Paré · NCT06044922 · Data updated 2026-11-12

This study is testing if measuring heart rate variability can help doctors predict brain injury in patients who have had a cardiac arrest and are in the ICU.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment200 (estimated)
SponsorCMC Ambroise Paré
Academic / other
Locations5 sites (Brest, Brittany Region and 4 other locations)
StatusRecruiting
StartedOctober 23, 2024
Main results expectedDecember 15, 2027
Study endsDecember 15, 2027
Registry record updatedDecember 16, 2024
Trial IDNCT06044922 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients who are comatose with a Glasgow score of less than 8 after resuscitation from cardiac arrest and require sedation and targeted temperature management.

Probably not a fit

Patients who are dying, have a non-sinus rhythm, or are pregnant or breastfeeding may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the role of heart rate variability (HRV) as a potential early predictor of noxic brain injury in patients who have experienced cardiac arrest. Patients admitted to the intensive care unit (ICU) after resuscitation will undergo 24-hour Holter monitoring to assess their HRV. The study seeks to improve prognostication in comatose patients following restoration of spontaneous circulation (ROSC) by evaluating HRV alongside existing clinical and paraclinical tests. The goal is to enhance the accuracy of predicting neurological outcomes in these patients.

Why it matters

Potential benefit: If successful, this study could provide a reliable method for early identification of patients at risk for severe neurological impairment after cardiac arrest.

How similar studies have gone: While the use of heart rate variability in this context is a novel approach, other studies have explored various prognostic indicators in post-cardiac arrest care with varying degrees of success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Admitted in intensive care unit (ICU) after resuscitation from cardiac arrest (in-hospital or out-of-hospital)
* Coma (Glasgow score \< 8) after ROSC, requiring sedation and targeted temperature management for at least 24h

Exclusion Criteria:

* Dying patient (Limitation of life support techniques at admission to the ICU)
* Non-Sinus Rhythm
* Pregnant or breastfeeding women
* Patient under protection of the adults (guardianship, curators or safeguard of justice)
* Opposition by the trusted person or by the patient once he/she wakes up

Where it's running

  • Brest University Hospital
    Brest, Brittany Region, France
    Recruiting
  • Nantes University Hospital
    Nantes, Pays de la Loire Region, France
    Recruiting
  • Marseille University Hospital
    Marseille, Provence-Alpes-Côte d'Azur Region, France
    Recruiting
  • Ambroise Paré - Hartmann Private Hospital Group
    Neuilly-sur-Seine, Île-de-France Region, France
    Recruiting
  • Cochin Hospital
    Paris, Île-de-France Region, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.